324 related articles for article (PubMed ID: 34622504)
1. Randomized clinical trial: 7-day vonoprazan-based versus 14-day omeprazole-based triple therapy for Helicobacter pylori.
Bunchorntavakul C; Buranathawornsom A
J Gastroenterol Hepatol; 2021 Dec; 36(12):3308-3313. PubMed ID: 34622504
[TBL] [Abstract][Full Text] [Related]
2. Vonoprazan- vs proton-pump inhibitor-based first-line 7-day triple therapy for clarithromycin-susceptible Helicobacter pylori: A multicenter, prospective, randomized trial.
Sue S; Ogushi M; Arima I; Kuwashima H; Nakao S; Naito M; Komatsu K; Kaneko H; Tamura T; Sasaki T; Kondo M; Shibata W; Maeda S
Helicobacter; 2018 Apr; 23(2):e12456. PubMed ID: 29271026
[TBL] [Abstract][Full Text] [Related]
3. The Superiority of Vonoprazan-based First-line Triple Therapy with Clarithromycin: A Prospective Multi-center Cohort Study on Helicobacter pylori Eradication.
Sue S; Kuwashima H; Iwata Y; Oka H; Arima I; Fukuchi T; Sanga K; Inokuchi Y; Ishii Y; Kanno M; Terada M; Amano H; Naito M; Iwase S; Okazaki H; Komatsu K; Kokawa A; Kawana I; Morimoto M; Saito T; Kunishi Y; Ikeda A; Takahashi D; Miwa H; Sasaki T; Tamura T; Kondo M; Shibata W; Maeda S
Intern Med; 2017; 56(11):1277-1285. PubMed ID: 28566587
[TBL] [Abstract][Full Text] [Related]
4. Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line
Suzuki S; Gotoda T; Kusano C; Ikehara H; Ichijima R; Ohyauchi M; Ito H; Kawamura M; Ogata Y; Ohtaka M; Nakahara M; Kawabe K
Gut; 2020 Jun; 69(6):1019-1026. PubMed ID: 31915235
[TBL] [Abstract][Full Text] [Related]
5. Clinical impact of vonoprazan-based dual therapy with amoxicillin for H. pylori infection in a treatment-naïve cohort of junior high school students in Japan.
Gotoda T; Kusano C; Suzuki S; Horii T; Ichijima R; Ikehara H
J Gastroenterol; 2020 Oct; 55(10):969-976. PubMed ID: 32666199
[TBL] [Abstract][Full Text] [Related]
6. Vonoprazan-based triple therapy is effective for Helicobacter pylori eradication irrespective of clarithromycin susceptibility.
Okubo H; Akiyama J; Kobayakawa M; Kawazoe M; Mishima S; Takasaki Y; Nagata N; Shimada T; Yokoi C; Komori S; Kimura K; Hisada Y; Iwata E; Watanabe K; Yanagisawa N; Shiroma S; Shimomura A; Okahara K; Cho H; Uemura N
J Gastroenterol; 2020 Nov; 55(11):1054-1061. PubMed ID: 32930864
[TBL] [Abstract][Full Text] [Related]
7. Vonoprazan-based therapies versus PPI-based therapies in patients with H. pylori infection: Systematic review and meta-analyses of randomized controlled trials.
Liu L; Shi H; Shi Y; Wang A; Guo N; Li F; Nahata MC
Helicobacter; 2024; 29(3):e13094. PubMed ID: 38790090
[TBL] [Abstract][Full Text] [Related]
8. Vonoprazan-based triple therapy is non-inferior to susceptibility-guided proton pump inhibitor-based triple therapy for Helicobacter pylori eradication.
Tanabe H; Yoshino K; Ando K; Nomura Y; Ohta K; Satoh K; Ichiishi E; Ishizuka A; Otake T; Kohgo Y; Fujiya M; Okumura T
Ann Clin Microbiol Antimicrob; 2018 Jun; 17(1):29. PubMed ID: 29950163
[TBL] [Abstract][Full Text] [Related]
9. Helicobacter pylori Eradication with Proton Pump Inhibitors or Potassium-Competitive Acid Blockers: The Effect of Clarithromycin Resistance.
Matsumoto H; Shiotani A; Katsumata R; Fujita M; Nakato R; Murao T; Ishii M; Kamada T; Haruma K; Graham DY
Dig Dis Sci; 2016 Nov; 61(11):3215-3220. PubMed ID: 27659671
[TBL] [Abstract][Full Text] [Related]
10. Vonoprazan versus conventional proton pump inhibitor-based triple therapy as first-line treatment against Helicobacter pylori: A multicenter retrospective study in clinical practice.
Shichijo S; Hirata Y; Niikura R; Hayakawa Y; Yamada A; Mochizuki S; Matsuo K; Isomura Y; Seto M; Suzuki N; Suzuki H; Yamamoto S; Sugimoto T; Omae T; Okamoto M; Watabe H; Togo G; Takano N; Fukui K; Ito Y; Koike K
J Dig Dis; 2016 Oct; 17(10):670-675. PubMed ID: 27534444
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Vonoprazan and Amoxicillin Dual Therapy for Helicobacter pylori Eradication: A Systematic Review and Meta-Analysis.
Zhang WL; Lin BS; Li YY; Ding YM; Han ZX; Ji R
Digestion; 2023; 104(4):249-261. PubMed ID: 37015201
[TBL] [Abstract][Full Text] [Related]
12. Dual Therapy with Vonoprazan and Amoxicillin Is as Effective as Triple Therapy with Vonoprazan, Amoxicillin and Clarithromycin for Eradication of Helicobacter pylori.
Furuta T; Yamade M; Kagami T; Uotani T; Suzuki T; Higuchi T; Tani S; Hamaya Y; Iwaizumi M; Miyajima H; Umemura K; Osawa S; Sugimoto K
Digestion; 2020; 101(6):743-751. PubMed ID: 31434101
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of Vonoprazan for Helicobacter pylori Eradication.
Kiyotoki S; Nishikawa J; Sakaida I
Intern Med; 2020 Jan; 59(2):153-161. PubMed ID: 31243237
[TBL] [Abstract][Full Text] [Related]
14. Clinical trial: seven-day vonoprazan- versus 14-day proton pump inhibitor-based triple therapy for first-line Helicobacter pylori eradication.
Ang D; Koo SH; Chan YH; Tan TY; Soon GH; Tan CK; Lin KW; Krishnasamy-Balasubramanian JK; Wong YJ; Kumar R; R R; Tan Y; Ong PJ; Tan YJ; Li JW; Kwek AB; Ang TL
Aliment Pharmacol Ther; 2022 Aug; 56(3):436-449. PubMed ID: 35665947
[TBL] [Abstract][Full Text] [Related]
15. Systematic review with meta-analysis: the efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication.
Jung YS; Kim EH; Park CH
Aliment Pharmacol Ther; 2017 Jul; 46(2):106-114. PubMed ID: 28497487
[TBL] [Abstract][Full Text] [Related]
16. Vonoprazan, a Novel Potassium-Competitive Acid Blocker, Should Be Used for the Helicobacter pylori Eradication Therapy as First Choice: A Large Sample Study of Vonoprazan in Real World Compared with Our Randomized Control Trial Using Second-Generation Proton Pump Inhibitors for Helicobacter pylori Eradication Therapy.
Ozaki H; Harada S; Takeuchi T; Kawaguchi S; Takahashi Y; Kojima Y; Ota K; Hongo Y; Ashida K; Sakaguchi M; Tokioka S; Sakamoto H; Furuta T; Tominaga K; Higuchi K
Digestion; 2018; 97(3):212-218. PubMed ID: 29393194
[TBL] [Abstract][Full Text] [Related]
17. Vonoprazan-Based Triple-Therapy Could Improve Efficacy of the Tailored Therapy of Helicobacter pylori Infection.
Shinmura T; Adachi K; Yamaguchi Y; Izawa S; Hijikata Y; Ebi M; Funaki Y; Ogasawara N; Sasaki M; Kasugai K
J Gastrointestin Liver Dis; 2019 Dec; 28(4):389-395. PubMed ID: 31826057
[TBL] [Abstract][Full Text] [Related]
18. Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the United States and Europe: Randomized Clinical Trial.
Chey WD; Mégraud F; Laine L; López LJ; Hunt BJ; Howden CW
Gastroenterology; 2022 Sep; 163(3):608-619. PubMed ID: 35679950
[TBL] [Abstract][Full Text] [Related]
19. Lower impact of vonoprazan-amoxicillin dual therapy on gut microbiota for Helicobacter pylori eradication.
Horii T; Suzuki S; Takano C; Shibuya H; Ichijima R; Kusano C; Ikehara H; Gotoda T
J Gastroenterol Hepatol; 2021 Dec; 36(12):3314-3321. PubMed ID: 34107551
[TBL] [Abstract][Full Text] [Related]
20. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a prospective randomized study.
Seddik H; Ahid S; El Adioui T; El Hamdi FZ; Hassar M; Abouqal R; Cherrah Y; Benkirane A
Eur J Clin Pharmacol; 2013 Sep; 69(9):1709-15. PubMed ID: 23695545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
